logo
Rediscovering the 'Forgotten Creators' of the German atomic bomb

Rediscovering the 'Forgotten Creators' of the German atomic bomb

Yahoo05-03-2025

EDITOR'S NOTE: This 'Historically Speaking' column contains the opinions of Dr. Todd H. Rider based upon the research and information contained in his book, 'Forgotten Creators: How German-Speaking Scientists and Engineers Invented the Modern World, And What We Can Learn from Them.' [https://riderinstitute.org/revolutionary-innovation/]
I now bring to you "Historically Speaking" readers an interesting insight into Germany during the Manhattan Project and World War II era. This one is based on extensive research and is published online for your review. Rider has also been featured on the YouTube series, "Hidden History: Stories from the Secret City. View this story online for the direct links or search on YouTube to watch the five episodes.
Part 1: https://www.youtube.com/watch?v=E0j4vsrz5XE
Part 2: https://www.youtube.com/watch?v=t1pPh048r0o
Part 3: https://www.youtube.com/watch?v=LQ8AQm6kboY
Part 4: https://www.youtube.com/watch?v=DHss4fDGCAY
Part 5: https://www.youtube.com/watch?v=SfYvRarCrg8
Get ready to have your mind filled with new information regarding the history of German atomic weapons.
***
Spring 2025 is the 80th anniversary of the end of the World War II German nuclear weapons program. Although the standard historical view since the war has been that the German nuclear program was small and primitive compared to the U.S. Manhattan Project, recently declassified and rediscovered archival documents reveal a different story.
According to information now available, between 1938 and 1945, Germany acquired thousands of tons of uranium and thorium ores from German territory, Poland, Czechoslovakia, Romania, Bulgaria, Belgium, Portugal, and possibly additional countries.
One route to producing fission fuel for nuclear weapons is enriching uranium - separating the highly fissionable uranium-235 isotope that constitutes approximately 0.72% of natural uranium from the rest that is relatively inert. During World War II, the United States enriched uranium primarily using a combination of 'calutrons' or electromagnetic separators (the Oak Ridge Y-12 facility) and gaseous thermal diffusion (the Oak Ridge K-25 facility).
Documents now available show that the Nobel-Prize-winning German physicist Dr. Gustav Hertz invented gaseous thermal diffusion enrichment in 1923, and the German government considered his research so important that he was able to work throughout the war despite his Jewish ancestry. In 1940, Auergesellschaft, a major German uranium company, invented an improved method of diffusion enrichment.
When Soviet forces entered Germany in 1945, they discovered that factories in the town of Neustadt an der Orla were uniquely skilled at producing nickel membrane filters for diffusion enrichment. What exactly had those factories been doing during the war?
In September 1946, Gen. Leslie Groves of the Manhattan Project sent Percival C. Keith, chief designer of the Oak Ridge K-25 plant, on a top-secret, two-week trip to Czechoslovakia. What mission would have required Keith's unique knowledge and would have justified the risk if he were captured by Czech or Soviet forces? Was Keith sent to inspect, strip, or sabotage a former German enrichment plant in Czechoslovakia?
Unfortunately, all other details are still classified. What we do know from the available documents is that Gustav Hertz, personnel from Auergesellschaft, those factories in Neustadt an der Orla, and resources from Czechoslovakia all played vital roles in the postwar Soviet nuclear weapons program.
Similarly, rediscovered archival documents reveal the German scientist Manfred von Ardenne, one of the inventors of television and the electron microscope, built a prototype calutron electromagnetic isotope separator in 1941. After successfully demonstrating his calutron, he called upon the German government and German industry to mass-produce his calutrons for large-scale uranium enrichment.
Documents from the U.S. Army Air Forces and Office of Special Services (OSS) reveal at least three large facilities were built for von Ardenne's machines and at least one of those facilities was destroyed by Allied bombing. Further information about this wartime work remains classified, although von Ardenne is known to have played a leading role in the postwar Soviet nuclear program.
Perhaps most importantly, Germany developed gas centrifuges, which are more efficient than calutrons and gaseous diffusion for uranium enrichment, and which therefore have now become the preferred method of enrichment worldwide. Documents show the German scientist Dr. Georg Bredig invented gas centrifuges sometime before 1895.
By World War II, uranium gas centrifuges were being produced in Kiel (by two different groups), Munich, Freiburg, Göttingen, Thuringia, Breslau (now Wrocław, Poland), and even factories in nominally neutral Switzerland for export back to Germany. How many uranium gas centrifuges did Germany produce and use during the war? Again, the details remain unavailable even 80 years later.
If Germany had built one large Oak-Ridge-like facility for all its uranium enrichment machines, it would have been straightforward for Allied bombers to destroy that facility. To minimize the risk from Allied bombing, Germany would have been strongly motivated to divide up its uranium enrichment machines among many smaller sites far apart, especially in the eastern regions of German-controlled territory (further from United States/United Kingdom bombing) and in the numerous large underground facilities that were highly resistant to aerial bombing. That is what Germany did with most of its other major industries as the war progressed. Indeed, a declassified October 1944 report from a highly placed Office of Strategic Services (OSS) spy cites several leading German industrialists as privately admitting that is exactly how Germany distributed its nuclear production facilities.
Other declassified wartime and early postwar documents name many of the German nuclear sites: twin I.G. Farben factories in Opava and Ostrava, Czechoslovakia, said to have 30,000 workers each and to be producing an important new type of explosive material for nuclear weapons; a similar 30,000-person facility underground in Thuringia; underground factories with huge numbers of workers making explosive nuclear material south of Hamburg; one or more uranium enrichment facilities on the outskirts of Berlin; an underground facility at Redl-Zipf, Austria processing what sounds like uranium hexafluoride through hundreds of unusual vertical cylindrical 'boilers' that sound like centrifuges or gaseous diffusion cells; heavily guarded and energy-consuming underground facilities near Landsberg in southeastern Germany that were making a critical new explosive material; a similar heavily guarded underground facility at Dubnica (now in Slovakia); highly secretive underground facilities near Stechovice (now in Czechia) powered by a German-built hydroelectric plant; facilities in Silesia (now part of Poland); and many other specific sites in Germany, Poland, Czechoslovakia, and Austria.
From the official Manhattan District history, during the final year of the war, all of Oak Ridge (both the facilities and the town itself) consumed an average of 0.189 gigawatts of electrical power. According to postwar reports by the U.S. Strategic Bombing Survey and the British Intelligence Objectives Subcommittee, at the end of 1944 the Greater German Reich was producing over 22 gigawatts of power despite all the Allied bombing. Including all other countries aiding Germany during the war, the total was probably around twice that amount.
Thus, operating enrichment facilities fully comparable to Oak Ridge would have required less than 0.86% of the power of the Greater German Reich, or probably less than 0.5% of the total power aiding Germany. Other documents indicate that German enrichment (especially centrifuges) was more efficient than Oak Ridge and that German bomb designs used methods more efficient than the U.S. "Little Boy" atomic bomb, so Germany would have needed much less power than Oak Ridge.
Another route to producing fission fuel for nuclear weapons is to use a fission reactor to convert natural uranium-238 into highly fissionable plutonium-239, or alternatively, to convert natural thorium-232 into highly fissionable uranium-233. For that purpose, the United States built several large graphite-moderated fission reactors at Hanford, Washington during and after World War II, plus several large heavy-water-moderated fission reactors at the Savannah River Site in South Carolina after the war.
The most famous wartime fission reactor in Germany was a small experimental reactor that was supervised by Dr. Werner Heisenberg and his associates and that never managed to achieve criticality (self-sustaining fission reactions) by the end of the war. However, recently rediscovered archival documents mention several other wartime reactors that may have achieved criticality and may have also been much larger.
A U.S. aerial surveillance photo of St. Georgen an der Gusen, Austria from March 15, 1945, shows what appears to be largely underground octagonal, pool-type fission reactors under construction or operational. An aerial surveillance photo of this same site on April 16, 1945, shows that German forces filled the site with earth and concrete and sealed it before U.S. troops arrived.
Surviving Austrian construction plans for this site list 'two atomic piles.' 1944 Austrian train logbooks show that several other suspected nuclear sites sent regular shipments of codenamed products to this Gusen site. The cover letter for a 1946 U.S. Army Air Forces report on this site is prominently hand-labelled 'Underground Pile' with three underlines - and the actual report is still classified. After the war, the son of the SS commandant of Gusen stated the purpose of the facility was to produce atomic bombs.
Of the reported 30-40 kilometers of tunnels at this underground facility, only one small portion is now opened to the public twice per year - and it contains such a high concentration of radioactive gases that it must be thoroughly ventilated before each public opening, visitors cannot remain in the tunnel longer than one hour, and a plastic barrier had to be installed to block even higher levels of radioactive gases coming from the off-limits tunnels beyond. Requests to conduct industrial archaeological excavations at the site have been rejected by the Austrian government.
Other archival documents mention known or suspected wartime fission reactors at Leverkusen, Hamburg, Leipzig, Lichterfelde, Gottow, Unterraderach, Bodenbach (now Decin, Czechia), Königsberg (now Kaliningrad, Russia), an underground installation in Thuringia, and perhaps other sites, as well. Once again, detailed reports on those sites remain unavailable to this day.
Most reactors include a moderator material that increases the probability that neutrons released by one fission reaction will cause more fission reactions. The U.S. nuclear program used a graphite moderator in its Hanford reactors and heavy water (oxygen with deuterium instead of regular light hydrogen) moderator in its Savannah River reactors.
It is well known that Germany was receiving shipments of heavy water from the Vemork plant in German-occupied Norway, and that Allied forces and the Norwegian resistance launched several attacks against that plant. Recently rediscovered documents indicate Germany was also receiving heavy water from at least 24 other plants all over German-controlled Europe. Detailed reports on those heavy water plants remain classified. The fact that Germany was producing heavy water at ~25 or more plants despite other urgent wartime needs strongly suggests that the heavy water was required for operational fission reactors or other aspects of a nuclear weapons program.
In fact, currently available documents show wartime Germany was also producing enormous quantities of other materials that a serious nuclear weapons program would require: tens of thousands of tons of graphite, thousands of tons each of fluorine, aluminum, calcium, nickel, and cadmium, hundreds of tons of lithium, tons of beryllium and zirconium, and large quantities of boron. Some sites such as I.G. Farben's Bitterfeld facility were producing multiple nuclear-related materials all at the same location. These activities began as early as 1938 and continued as a high priority to the very end of the war in Europe.
In Part 2 next week, we will discuss what recently rediscovered archival documents tell us about the design, construction, and successful testing of German atomic bombs, as well as the transfer of German nuclear technologies and personnel to the United States and other countries after the war.
All of the archival evidence mentioned in these two articles and much more is available for free at: https://riderinstitute.org/revolutionary-innovation/ .Everything discussed there and in these articles is based entirely on unclassified and declassified sources. If you find this evidence of interest, please use it as a starting point and see how much more evidence you can find in public archives and private collections around the world, or (very carefully, with all appropriate precautions, permissions, and procedures!) at some of the suspected wartime sites in Europe.
***
Thanks Todd! What a great start to the insights he has discovered. Look forward to the next part of the story.
D. Ray Smith is the city of Oak Ridge historian. His "Historically Speaking" columns are published weekly in The Oak Ridger.
This article originally appeared on Oakridger: Rediscovering the 'Forgotten Creators' of the German atomic bomb

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

Yahoo

time3 hours ago

  • Yahoo

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio

'Operation Crossbow' Blu-Ray Review - A Thrilling Wartime Espionage Tale
'Operation Crossbow' Blu-Ray Review - A Thrilling Wartime Espionage Tale

Geek Vibes Nation

time7 hours ago

  • Geek Vibes Nation

'Operation Crossbow' Blu-Ray Review - A Thrilling Wartime Espionage Tale

A fearsome rumor reaches Britain's World War II command. The Nazis are developing rocket technology that could rain death on London and then New York. Quickly, England develops a plan to send saboteurs into the sites manufacturing the rockets. Just moments after the carefully chosen commandos parachute into the drop zone, their pilot receives an urgent message: The mission may be compromised. Abort. Operation Crossbow is the partly fact-based tale of how that team succeeded against daunting odds. Michael Anderson (The Dam Busters, Logan's Run) directs, guiding a huge cast in a film that builds to a spectacular finale, yet never neglects war's unsparing personal costs. As a record of a wartime espionage incursion and as an intrigue-filled thriller, Operation Crossbow is on both counts Operation Accomplished. For thoughts on Operation Crossbow, please check out my thoughts on No Streaming Required: Video Quality Warner Archive presents Operation Crossbow with a sterling 1080p master transfer released in 2019 in its original 2.35:1 aspect ratio sourced from a 2K scan of the Interpositive that looks like a dream. Viewers are unlikely to spot the difference between this and a scan from the Original Camera Negative, given the amazing effort from the label. The film exhibits no serious signs of wear and tear or debris. Even momentary softness during optical transitions that cannot be avoided is handled with care. The colors of the environments are striking with memorable touches in the clothing and production design. Each hue is ideally saturated for first-rate accuracy. Black levels are deep with impeccable stability throughout, and highlights similarly hold firm. Detail and clarity are of the highest order with the sumptuous natural film grain intact and resolved consistently. There are no unwanted digital fumbles such as compression artifacts, banding, or any other such issues. Warner Archive showed off with this one. Audio Quality The Blu-Ray comes with a DTS-HD 5.1 Master Audio track that comes to life quite memorably. There is quite a bit of chatter at the base in German with English subtitles, and the overwhelmingly English dialogue sounds great, as well. Things kick into gear in your speakers as you fully engage with the thrilling finale. The score from Ron Goodwin is used perfectly to transport you into this spy thriller filled with simmering emotions. Even when it is particularly active, it does not step on any important exchanges or background noises. There is no obvious age-related wear and tear to the track such as drop-outs, hissing, or popping. Warner Archive has put forth good work with this audio presentation. Optional English (SDH) subtitles are included for the feature film. Special Features A Look Back At Crossbow: A ten-minute archival featurette that takes a look at the real-life rocket program fictionalized in the feature film. Theatrical Trailer (2:36) Final Thoughts Operation Crossbow is a thrilling espionage movie that brings a personal touch to a very important wartime story. The movie takes some measures to feel authentic with Germans actually speaking in German with subtitles, and the movie establishes some heavy consequences to these heroic efforts. The performances are quite good all around, even if some of the tertiary characters could have been a bit more fully developed. This is definitely worth a watch for fans of wartime dramas. Warner Archive has released Blu-Ray featuring a stellar A/V presentation and a couple of special features. Recommended Operation Crossbow can be purchased directly through MovieZyng or various other online retailers. Note: Images presented in this review are not reflective of the image quality of the Blu-Ray. Disclaimer: Warner Archive has supplied a copy of this disc free of charge for review purposes. All opinions in this review are the honest reactions of the author.

Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

Yahoo

time11 hours ago

  • Yahoo

Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store